Showing results (1021-1030 of 1,084) with videos related to
Sort By:
Pageof 109
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 30, 2012
CCT244747 is a novel potent and selective CHK1 inhibitor with oral efficacy alone and in combination with genotoxic anticancer drugsMike I Walton, Paul D Eve, Angela Hayes, et al.Immunohorizons|December 22, 2022
Dam-Infant Rhesus Macaque Pairs to Dissect Age-Dependent Responses to SARS-CoV-2 InfectionStephanie N Langel, Carolina Garrido, Caroline Phan, et al.Journal of Medicinal Chemistry|January 18, 2017
Antimalarial Pyrido[1,2-a]benzimidazoles: Lead Optimization, Parasite Life Cycle Stage Profile, Mechanistic Evaluation, Killing Kinetics, and in Vivo Oral Efficacy in a Mouse ModelKawaljit Singh, John Okombo, Christel Brunschwig, et al.Cancers|September 5, 2020
Intronic TP53 Polymorphisms Are Associated with Increased Δ133TP53 Transcript, Immune Infiltration and Cancer RiskRamona A Eiholzer, Sunali Mehta, Marina Kazantseva, et al.Frontiers in Pharmacology|May 23, 2022
Semi-Synthetic Analogues of Cryptolepine as a Potential Source of Sustainable Drugs for the Treatment of Malaria, Human African Trypanosomiasis, and CancerYabalu Z Abacha, Arnold Donkor Forkuo, Stephen Y Gbedema, et al.Journal of Hepatology|November 5, 2021
Membrane-delimited signaling and cytosolic action of MG53 preserve hepatocyte integrity during drug-induced liver injuryYu Han, Sylvester Black, Zhengfan Gong, et al.Journal of Medicinal Chemistry|August 10, 2018
A Fragment-Derived Clinical Candidate for Antagonism of X-Linked and Cellular Inhibitor of Apoptosis Proteins: 1-(6-[(4-Fluorophenyl)methyl]-5-(hydroxymethyl)-3,3-dimethyl-1 H,2 H,3 H-pyrrolo[3,2- b]pyridin-1-yl)-2-[(2 R,5 R)-5-methyl-2-([(3R)-3-methylmorpholin-4-yl]methyl)piperazin-1-yl]ethan-1-one (ASTX660)Christopher N Johnson, Jong Sook Ahn, Ildiko M Buck, et al.Bioorganic & Medicinal Chemistry Letters|January 5, 1999
Benzimidazole derivatives as arginine mimetics in 1,4-benzodiazepine nonpeptide vitronectin receptor (alpha v beta 3) antagonistsR M Keenan, W H Miller, M A Lago, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 7, 2022
A Phase 1 First-in-Human Study of FS118, a Tetravalent Bispecific Antibody Targeting LAG-3 and PD-L1 in Patients with Advanced Cancer and PD-L1 ResistanceTimothy A Yap, Patricia M LoRusso, Deborah J Wong, et al.Journal of Medicinal Chemistry|August 14, 2025
Novel Inhibitors of Plasmodium Phosphatidylinositol 4-kinase IIIβ with Low Propensity for Resistance: Life Cycle Stage Activity and In Vivo Efficacy in a Humanized Mouse Malaria Infection ModelGodwin A Dziwornu, Mmakwena M Mmonwa, Dina Coertzen, et al.Pageof 109